- Home
- NSTS vs NRXP Comparison
NSTS vs NRXP Comparison
Compare NSTS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- NRXP
- Stock Information
- Founded
- NSTS 1921
- NRXP 2015
- Country
- NSTS United States
- NRXP United States
- Employees
- NSTS N/A
- NRXP N/A
- Industry
- NSTS Savings Institutions
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- NRXP Health Care
- Exchange
- NSTS Nasdaq
- NRXP Nasdaq
- Market Cap
- NSTS 63.0M
- NRXP 58.5M
- IPO Year
- NSTS N/A
- NRXP N/A
- Fundamental
- Price
- NSTS $11.18
- NRXP $3.18
- Analyst Decision
- NSTS
- NRXP Strong Buy
- Analyst Count
- NSTS 0
- NRXP 5
- Target Price
- NSTS N/A
- NRXP $31.40
- AVG Volume (30 Days)
- NSTS 3.7K
- NRXP 454.2K
- Earning Date
- NSTS 11-12-2025
- NRXP 11-13-2025
- Dividend Yield
- NSTS N/A
- NRXP N/A
- EPS Growth
- NSTS N/A
- NRXP N/A
- EPS
- NSTS N/A
- NRXP N/A
- Revenue
- NSTS $9,435,000.00
- NRXP N/A
- Revenue This Year
- NSTS N/A
- NRXP N/A
- Revenue Next Year
- NSTS N/A
- NRXP $395.09
- P/E Ratio
- NSTS N/A
- NRXP N/A
- Revenue Growth
- NSTS 69.39
- NRXP N/A
- 52 Week Low
- NSTS $10.70
- NRXP $1.12
- 52 Week High
- NSTS $13.32
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- NSTS 30.69
- NRXP 51.54
- Support Level
- NSTS $11.30
- NRXP $2.95
- Resistance Level
- NSTS $11.35
- NRXP $3.19
- Average True Range (ATR)
- NSTS 0.07
- NRXP 0.25
- MACD
- NSTS -0.00
- NRXP -0.04
- Stochastic Oscillator
- NSTS 2.08
- NRXP 24.16
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.